Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

10x Genomics (TXG) Gross Margin (2018 - 2026)

10x Genomics' Gross Margin history spans 8 years, with the latest figure at 68.09% for Q4 2025.

  • On a quarterly basis, Gross Margin rose 85.0% to 68.09% in Q4 2025 year-over-year; TTM through Dec 2025 was 69.05%, a 119.0% increase, with the full-year FY2025 number at 69.05%, up 119.0% from a year prior.
  • Gross Margin hit 68.09% in Q4 2025 for 10x Genomics, up from 67.32% in the prior quarter.
  • Over the last five years, Gross Margin for TXG hit a ceiling of 95.76% in Q2 2021 and a floor of 62.18% in Q3 2023.
  • Historically, Gross Margin has averaged 73.05% across 5 years, with a median of 71.25% in 2025.
  • Biggest five-year swings in Gross Margin: skyrocketed 1919bps in 2021 and later crashed -1993bps in 2022.
  • Tracing TXG's Gross Margin over 5 years: stood at 80.77% in 2021, then fell by -5bps to 76.43% in 2022, then fell by -18bps to 62.93% in 2023, then increased by 7bps to 67.24% in 2024, then rose by 1bps to 68.09% in 2025.
  • Business Quant data shows Gross Margin for TXG at 68.09% in Q4 2025, 67.32% in Q3 2025, and 72.34% in Q2 2025.